While allogeneic stem cell transplantation (SCT) is curative for a significant number of patients with AML, relapse of disease within the bone marrow and/or extramedullary (EM) sites following high-dose therapy continues to limit the success of this treatment. Between October 1985 and December 1996, 81 adults underwent allogeneic SCT for de novo AML at our centre. Fortytwo patients remain alive and free of leukaemia with a median follow-up of 50 months. The 5-year actuarial event-free survivals (EFS) for all patients and for those undergoing SCT in CR1 or with advanced disease were 46% (95% confidence interval (CI) 34-58%), 63% (CI 46-76%), and 19% (CI 7-36%), respectively. Twentytwo patients relapsed at a median of 8 (range 1.6-54.5) months with the actuarial risk of relapse for all, CR1 and advanced disease patients being 38%, (CI 27-52%), 23% (CI 13-40%) and 68% (CI 46-88%), respectively. Ten patients relapsed at EM sites; six of these (27% of relapses) had an isolated EM relapse at a median of 31 (range 8.5-54) months. Three of the patients with isolated EM relapse survived у24 months following relapse and two patients remain disease-free at 29+ and 33+ months. BuCy conditioning followed by allogeneic SCT in AML results in satisfactory EFS although there is a significant risk of late isolated EM relapse. Keywords: acute myelogenous leukemia; extramedullary relapse; allogeneic BMT Allogeneic stem cell transplantation (SCT) is an effective therapy for patients with AML.
Summary:
While allogeneic stem cell transplantation (SCT) is curative for a significant number of patients with AML, relapse of disease within the bone marrow and/or extramedullary (EM) sites following high-dose therapy continues to limit the success of this treatment. Between October 1985 and December 1996, 81 adults underwent allogeneic SCT for de novo AML at our centre. Fortytwo patients remain alive and free of leukaemia with a median follow-up of 50 months. The 5-year actuarial event-free survivals (EFS) for all patients and for those undergoing SCT in CR1 or with advanced disease were 46% (95% confidence interval (CI) 34-58%), 63% (CI 46-76%), and 19% (CI 7-36%), respectively. Twentytwo patients relapsed at a median of 8 (range 1.6-54.5) months with the actuarial risk of relapse for all, CR1 and advanced disease patients being 38%, (CI 27-52%), 23% (CI 13-40%) and 68% (CI 46-88%), respectively. Ten patients relapsed at EM sites; six of these (27% of relapses) had an isolated EM relapse at a median of 31 (range 8.5-54) months. Three of the patients with isolated EM relapse survived у24 months following relapse and two patients remain disease-free at 29+ and 33+ months. BuCy conditioning followed by allogeneic SCT in AML results in satisfactory EFS although there is a significant risk of late isolated EM relapse. Keywords: acute myelogenous leukemia; extramedullary relapse; allogeneic BMT Allogeneic stem cell transplantation (SCT) is an effective therapy for patients with AML. [1] [2] [3] Long-term event-free survival (EFS) can be achieved in approximately 60% of patients undergoing SCT in first complete remission (CR1) [4] [5] [6] [7] [8] [9] and 25-30% of those with more advanced disease.
1,2,4,10,11 However, there remains some controversy regarding the optimal transplant preparative regimen in AML. For patients transplanted in CR1, one randomized study demonstrated a regimen employing TBI to be superior to busulfan/cyclophosphamide (BuCy) conditioning, 7 while another showed the regimens to be equivalent. 8 One of the contributing factors to an unsuccessful result with SCT regardless of the preparative regimen utilized is relapse, occurring in 20-25% and 30-50% of AML patients transplanted during CR1 or with advanced disease, respectively. 1, 2, 4, 7, 9 The site of relapse after a TBI-based preparative regimen is usually the marrow with or without extramedullary (EM) disease. 12 Isolated EM relapse occurred in only 13% of patients developing recurrent disease after TBI conditioning in one study. 12 Little is known about the risk of isolated EM relapse of AML following BuCy with a small number of such patients reported recently in a survey by the European Group for Blood and Marrow Transplantation (EBMT) of more than 3000 AML transplants. 13 The present review was prompted by the observation that several patients receiving allogeneic SCT after BuCy at our institution experienced isolated EM relapse.
Patients and methods

Patient characteristics
Between October 1985 and December 1996, 81 patients with de novo AML underwent related-donor SCT; patient characteristics are shown in Table 1 .
Conditioning regimen
A diagnostic lumbar puncture was performed on day Ϫ8 with the administration of cytosine arabinoside 30 mg/m 2 intrathecally. All patients (with one exception) then received modified BuCy 4 with doses based on the lesser of actual or ideal body weight. Busulfan was given at a dose of 1 mg/kg orally every 6 h for 4 days from days Ϫ7 to Ϫ4. Patients vomiting within 1 h of busulfan administration had the dose repeated and those vomiting two consecutive doses received subsequent doses via a naso-duodenal tube. Cyclophosphamide at a dose of 60 mg/kg was given i.v. over 2 h on days Ϫ3 and Ϫ2. One patient with pre-existing hepatic dysfunction was given a modified Bu (12 mg/kg) Cy (200 mg/kg) regimen. Patients routinely received phenytoin as anti-seizure prophylaxis while on busulfan with doses adjusted to maintain therapeutic drug levels.
14 Hyperhydration with i.v. fluids at 3 l/m 2 /day was given with the cyclophosphamide for uroepithelial protection, except between October 1987 and January 1990, when 24 patients were randomly assigned to receive hyperhydration or mesna. 15 
Stem cell transplantation
Seventy-six patients received stem cells (75 marrow; one peripheral blood) from a histocompatible sibling donor. Three received marrow from a haploidentical 1-antigen mismatched related-donor and two received marrow from a phenotypically identical parent. Marrow manipulation was not performed except when ABO-incompatibility necessitated plasma and/or erythrocyte depletion. 16 The median number of nucleated marrow cells infused was 3.7 (range 0.67-8.8) × 10 8 /kg.
GVHD prophylaxis
Sixty-three patients received cyclosporin A (CsA) and short-course methotrexate (MTX) with (seven patients) 17 or without (56 patients) 18 folinic acid. Thirteen patients received CsA and methylprednisolone (MP), 19 two patients CsA alone, one patient MTX alone and one patient CsA, MTX and MP. One patient at high risk for GVHD (parous female donor) was given GVHD prophylaxis consisting of CsA, MTX and anti-CD5/ricin immunotoxin (XomaZyme, XOMA Corporation, Berkeley, CA, USA). 20 Whole blood CsA levels were measured twice weekly and maintained at 200-400 g/l until day +100 after which a standard 3-month taper was instituted. GVHD was graded according to accepted standard criteria. 21, 22 Supportive care
Patients were treated in the HEPA-filtered, positive pressure Leukemia and Bone Marrow Transplantation Unit at the Vancouver Hospital and Health Sciences Centre. Low bacterial content food and Hickman catheters were used routinely. Empiric i.v. antibiotics, amphotericin B, acyclovir, CMV-negative blood products, high-titre CMV immunoglobulin products, ganciclovir and total parenteral nutrition were given as required. Hepatic veno-occlusive disease (VOD) prophylaxis with low-dose i.v. heparin (100 units/kg/day) 23 was given routinely after September 1992. All patients received fluconazole (200-400 mg/day i.v.) as antifungal prophylaxis from June 1992 until December 1994 when this was changed to i.v. amphotericin B at 10 mg/m 2 /day. Hematopoietic growth factors were initially used only in instances of primary or secondary graft failue (four patients). Beginning in November 1995, four patients received granulocyte colony-stimulating factor (G-CSF) as part of a separate study investigating the role of G-CSF in ganciclovir-induced neutropenia; one additional patient was given G-CSF due to documented deep fungal infection that occurred prior to engraftment.
Statistical methods
The actuarial EFS, non-relapse mortality, GVHD, and relapse probabilities were calculated using the product limit estimates of Kaplan and Meier. 24 
Results
Survival
Forty-two of 81 patients are alive and free of leukaemia with a median follow-up of 49.5 (range 2-170) months. One of these patients required a second SCT for late graft failure. The 5-year actuarial EFS for all, CR1 and advanced disease patients were 46% (95% CI 34-58%), 63% (CI 46-76%), and 19% (CI 7-36%), respectively ( Figure 1 ). The corresponding 5-year actuarial overall survivals for the three groups were 48% (CI 35-60%), 63% (CI 49-79%), and 19% (CI 6-38%), respectively.
Non-relapse mortality (NRM)
Seventeen patients died from causes other than relapse. Six deaths were attributed to acute/chronic GVHD, four to infection (two CMV, two Aspergillus), three to hepatic VOD, two to hemorrhage (one central nervous system (CNS), one gastrointestinal (GI)), and one each to graft failure and second malignancy (lung). Five of 11 patients with induction failure AML experienced NRM (two GVHD, two infection, one VOD). The 5-year probabilities of NRM for all, CR1 and advanced disease patients were 25% (CI 16-39%), 18% (CI 9-36%) and 40% (CI 21-67%), respectively.
GVHD
The actuarial probabilities of developing grades II-IV and grades III-IV acute GVHD were 39% (CI 29-51%) and 8% (CI 4-16%), respectively. The actuarial risk of developing limited or extensive chronic GVHD was 54% (CI 42-67%).
Relapse
Twenty-two patients relapsed at a median of 8 (range 1.6-54) months following SCT. Of 50 patients receiving SCT in CR1, only eight relapsed at a median of 12.8 (range 3.5-54) months while 14 of 31 patients with advanced disease at SCT (including five of 11 with induction failure AML) relapsed at a median of 7.6 (range 1.6-50) months. The 5-year actuarial probabilities for relapse in all, CR1 and advanced disease patients were 38% (CI 27-52%), 23% (CI 13-40%) and 68% (CI 46-88%), respectively ( Figure 2 ).
Incidence of EM relapse
Twelve of 22 patients who relapsed did so in the marrow alone at a median of 5.8 (range 2.4-17.3) months. Six patients experienced an isolated EM relapse at a median of 31.1 (range 8.5-54) months for a 5-year actuarial prob- ability of 16% (CI 7-32%) (Figure 3) . The remaining four patients had concurrent marrow and EM relapse. Relapse more than 18 months following SCT occurred in only five patients and all involved EM sites (four isolated, one with marrow relapse).
Isolated EM relapse patient characteristics
Characteristics of patients with isolated EM relapse are shown in Table 2 ; only one of these patients (UPN 963) had a history of EM disease prior to SCT. None of the six patients received hematopoietic growth factors following SCT. Two of the patients developed both grade II acute GVHD and chronic GVHD, one patient developed grade II acute without chronic GVHD, and two patients developed de novo chronic GVHD; one patient did not show any evidence of acute or chronic GVHD. Sites of relapse included testis (one patient), para-aortic (PA) lymph nodes (one patient), testis and PA nodes (one patient), CNS (two patients), and chest wall (one patient). Three patients had FAB M3 subtype, two patients with documented t(15;17) and one patient with classic M3 morphology and coagulopathy at diagnosis. The two patients with t(15;17) also had additional cytogenetic abnormalities consisting of tetrasomy 8 (UPN 537) and three additional copies of chromosome 21 (UPN 792). Two patients had t(8;21) but also had other karyotypic abnormalities (del 7q (UPN 768) and ϪY (UPN 963)). Isolated EM relapse occurred after SCT for CR1 (three patients) as well as for advanced disease (three patients).
Treatment and outcome of isolated EM relapse
Both patients (UPN 531 and 633) with isolated CNS EM relapse died of persistent disease (2 days and 4.5 months after relapse) despite local radiotherapy/intrathecal chemotherapy. The other four patients also received local radiotherapy (in two to the opposite testicle after unilateral orchidectomy, in one to para-aortic nodes and in one to the chest wall). One patient (UPN 792) with M3 subtype remains in remission 29 months later, having also received a course of all-trans retinoic acid (ATRA); three patients have developed recurrent EM disease. Of these latter three patients, one (UPN 963) died of disease without further treatment 7 months after relapse. One patient (UPN 537) developed three EM recurrences (para-aortic nodes, psoas muscle and skin without morphologic evidence of marrow UPN = unique patient number; FAB = French-American-British; MOS = months; SCT = stem cell transplantation; GVHD = graft-versus-host disease; A = acute; C = chronic; M = male; F = female; CR = complete remission; E = extensive; PA = para-aortic; Rel = relapse.
relapse) which were initially successfully treated with ATRA and standard systemic chemotherapy before he died of progressive disease 24 months after relapse. Finally, one patient (UPN 768) had chemotherapy for a second EM relapse (para-aortic nodes without morphologic evidence of marrow relapse) and remains free of disease 33 months after first relapse.
Discussion
These single institution results for the treatment of AML with SCT following BuCy conditioning are similar to those reported previously for TBI and nonTBI-containing regimens. [1] [2] [3] [4] [5] [6] [7] [8] [9] As expected, patients with advanced disease had a higher incidence of both relapse and non-relapse mortality 1,2,4,8 when compared to patients transplanted in CR1. However, the high incidence of isolated EM relapse was suprising and this is the focus of discussion.
Almost one-half of the relapses observed in our study population involved EM disease and six of 22 relapses (27%) were isolated EM relapses. Furthermore, all five relapses occurring beyond 18 months post-SCT involved EM sites (four isolated). Prior to the routine use of BuCy in the late 1980s and as conditioning for unrelated donor or second SCT, we have treated 54 de novo AML patients with TBI regimens. There have been 16 patients that have relapsed following TBI and only one patient experienced an isolated EM recurrence.
There are few published data available on the incidence of isolated EM relapse post-SCT, with one exception. In a series from Seattle of 455 AML SCT, 95 patients relapsed following Cy/TBI with 12 (13%) of these having been isolated EM relapses. 12 The site of relapse is not specified in previous reports of BuCy-treated patients 4, 7, 8 and only four patients in an EBMT review of AML transplants were noted to have an isolated EM relapse following a BuCy preparative regimen. 13 Late relapses of AML post-SCT are uncommon, 2, 7, [25] [26] [27] and there are few reports on the specific incidence of late EM relapse. However, in the EBMT survey, there were 21 patients with isolated EM relapses of AML at a median of 20 months post-SCT and six patients relapsed beyond 36 months.
13
The risk factors for EM disease in AML have recently been reviewed and include M4/M5 FAB subtypes, t(8;21) and inv(16) karyotypic abnormalities, and T cell (CD2, CD4 and CD7) or CD56 cell surface markers. 28 These risk factors for EM disease were also seen in our patients with isolated EM relapse post-SCT. Two of three patients known to have t(8;21) at diagnosis subsequently had isolated EM relapse although the closely correlated CD56 cell surface marker 29 was not tested in either patient. One of these patients (UPN 963) had received radiotherapy for a pre-SCT EM relapse and underwent SCT in CR2. Although the t(8;21) has generally been associated with a good prognosis, it has been suggested that this may not be true for those patients with a history of EM disease. 30 It is of particular interest that three patients with isolated post-SCT EM relapse had AML-M3, a disease that has rarely been reported to involve EM sites. 28, 31 However, of the five published cases of isolated AML EM relapse following BuCy, including an earlier report from our centre, 13,32 three of the patients had AML-M3. It could be argued that the additional cytogenetic abnormalities in two of our three AML-M3 patients (tetrasomy 8 and three extra copies of chromosome 21, respectively), signified a more aggressive form of AML-M3 with a propensity for EM disease. Such karyotypic clonal evolution has been shown to influence prognosis 33 although it should be emphasized that these additional cytogenetic changes were present at diagnosis and at pre-SCT relapse in both patients but EM disease appeared for the first time only following SCT.
Recent reports suggest that EM relapse of AML-M3 may be more common in certain ethnic groups and as a result of the increasing use of ATRA. 31 None of the three AML-M3 patients in our study had exposure to ATRA prior to SCT, although one (UPN 537), as we previously reported, 32 had received extensive isotretinoin (13-cis retinoic acid) maintenance therapy before transplant. Notably, of the three AML-M3 EM relapse patients, one was of East Indian, one was of Asian, and one was of Northern European descent.
The mechanism behind the EM localization of blasts has not yet been elucidated but experience has shown that the vast majority of patients with EM disease develop marrow disease if only local therapy is given. 28 This indicates that leukemic cells must be present in the marrow even in those patients in whom the EM disease appears to be isolated. Despite this, it seems reasonable to separate those patients who present with isolated EM relapse from those who relapse in the marrow as well. While in both groups it is likely that the adhesive properties of the leukemic cells determines the pattern of relapse, 34 in the former, it is conceivable that the pre-transplant conditioning may select for leukemic cells present outside the marrow and thus influence the relapse site. The fact that other centres utilizing the BuCy regimen have not reported a similar high incidence of isolated EM relapse may be due to short follow-up. In our experience, most cases of isolated EM relapse were late, four of six occurring more than 30 months post-SCT. This finding is supported by other literature reports which suggest that it is not uncommon for an isolated EM relapse to occur years after transplant. 13, 35 It is less easy to explain the apparently high incidence of isolated EM relapse in patients receiving BuCy when compared to TBI. However, as the cyclophosphamide given with both regimens is similar, a possible mechanism for the difference is that poor tissue levels of busulfan were achieved in some patients. As the tissue penetration of busulfan is adequate, 36 this implies that these patients also had correspondingly low plasma levels of busulfan. There is considerable interpatient variation in busulfan absorption and metabolism which may account for this. 37 An intercurrent study was performed at our centre which monitored plasma busulfan levels in SCT patients. Patients studied had a lower mean busulfan area under the curve (AUC) 38 than others have reported in adults receiving busulfan conditioning. 39 It is conceivable that the dilantin used at our centre for seizure prophylaxis in all patients 14 was responsible for the decrease in busulfan levels due to increased drug metabolism. 40 Two of the six patients with isolated EM relapse post-SCT participated in this study (UPN 768 and UPN 792) with both having parametric AUC values (265 and 225 g min/ml, respectively), far below our study mean (321 g min/ml). Low plasma busulfan levels have been correlated with an increased risk of relapse in a recent study involving patients with CML. 41 Finally, it was of particular interest that four patients relapsed in the testis (two patients) or CNS (two patients), raising the possibility that these relapses might have been prevented by aggressive prophylactic chemoradiotherapy.
Optimal therapy for patients with isolated EM relapse post-SCT remains controversial. Radiotherapy, local or systemic chemotherapy, second SCT and donor leukocyte infusions have all been utilized. 12, 13, 42 Long-term survival has been documented in up to one-third of patients with rare cases surviving 8-10 years beyond initial EM relapse. 12, 13 Factors predictive of prolonged survival have included early disease status at time of SCT and longer time from SCT to EM relapse. 12, 13 We could not confirm the former in our patient group since two of three CR1 patients with isolated EM relapse had short survival times. However, three of four patients relapsing at у30 months following SCT were relatively long-term survivors (24, 29+ and 33+ months post-EM relapse).
We have confirmed the general efficacy of allogeneic SCT following BuCy conditioning in AML. Although the overall relapse rate was not excessive, patients with advanced disease were particularly prone to recurrent AML. Most significantly, we have noted a higher rate of isolated EM relapse in our patients conditioned with BuCy than previously reported for Cy/TBI regimens, raising the possibility that this is related to the preparative regimen. This observation needs to be confirmed by other centres but has implications on the selection of myeloablative therapy, the role of monitoring of busulfan levels and the use of specific CNS and testicular prophylaxis.
